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Inflammatory bowel disease (IBD), includ-
ing Crohn disease (CD) and ulcerative
colitis (UC), is an autoimmune digestive
system disease (1). A recent cohort study
using the U.K. Clinical Practice Research
Datalink (CPRD) involving 7,231 dipep-
tidyl peptidase 4 inhibitor (DPP4i)
users with 49 IBD cases indicated that
new use of DPP4is over a median dura-
tion of 1.6 years was associated with IBD
risk in patients with type 2 diabetes
compared with other noninsulin antihy-
perglycemic drugs (hazard ratio 1.75,
95% CI 1.22, 2.49) (2). Current evidence
regarding the effect of DPP4is on IBD risk
is very limited. We thus performed a
disproportionality analysis using the U.S.
Food and Drug Administration Adverse
Event Reporting System (FAERS) data-
base, which contains all adverse events
spontaneously reported to the Food and
Drug Administration since 2004 (3).
We downloaded the FAERS data files
from 2004 1st quarter to 2017 3rd quar-
ter, used generic and trade names to
identify DPP4is (sitagliptin, saxagliptin,
linagliptin, alogliptin, and vildagliptin)
and comparator drugs, and identified
outcomes using Medical Dictionary for
Regulatory Activities terms. The primary
outcome was IBD (both CD and UC), and
secondary outcomes were CD and UC,
separately. The safety signal of DPP4is and
IBD was assessed by reporting odds ratio
(ROR) using two-by-two contingency ta-
bles (4). A signal was defined as an ROR
of$2. The data were analyzed by SAS 9.4
software (SAS Institute, Cary, NC).
We conducted three comparisons (Fig.
1). First, we compared DPP4is to all other
antidiabetic drugs, including metformin,
sulfonylureas, thiazolidinediones, glucagon-
like peptide 1 receptor agonists, sodium–
glucose cotransporter 2 inhibitors (SGLT2is),
insulin, a-glucosidase inhibitors, and
glinides.
Second, we compared DPP4is to two
classes of therapeutic alternatives:
thiazolidinediones (pioglitazone, rosig-
litazone) and SGLT2is (canagliflozin,
dapagliflozin, empagliflozin). These two
classes were selected because they are
used to treat similar stages of diabetes
and have no known association with IBD
risk.
Third, we compared DPP4is to
SGLT2is only, as SGLT2is are a new
class of antidiabetic drugs that may
have more similar reporting rates to
DPP4is.
For each comparison, we performed
sensitivity analyses by restricting to
events with drugs reported as 1) “pri-
mary suspect” (those drugs directly sus-
pected of causing the adverse events
when submitted in the case report) or
as 2) “primary suspect” or “secondary
suspect,” respectively.
A total of 86 DPP4i-associated IBD
cases were extracted from FAERS
through 30 September 2017, of which
45 and 38 were reported as CD and UC
cases, respectively. The RORs (95% CIs)
for IBD, CD, and UC were 1.43 (1.13,
1.81), 1.39 (1.01, 1.92), and 1.66 (1.16,
2.37), respectively, compared with all
other antidiabetic drugs (Fig. 1). Sensi-
tivity analyses restricted to primary
suspect cases, or primary suspect and
secondary suspect cases, moved RORs
toward the null (95%CI crossed 1).When
compared with thiazolidinediones and
SGLT2is, the RORs for IBD, CD, and UC
were 1.69 (1.29, 2.22), 2.63 (1.74, 3.99),
and 1.19 (0.81, 1.75), respectively; the
ROR for IBD was 3.49 (1.89, 6.44) when
restricted to primary suspect cases.
When compared with SGLT2is only,
the ROR for IBD was 1.50 (0.96, 2.34).
Overall, across the three comparisons,
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sensitivity analyses were consistent with
the primary analysis but yielded lower
RORs (compared with other antidiabetic
drugs) or wider CIs (compared with ther-
apeutic alternatives).
In this analysis of the FAERS database,
we found a weak-to-moderate signal for
IBD associated with DPP4i use when
DPP4i was compared with therapeutic
alternatives.Our FAERSanalysis involving
184,516 DPP4i users with 86 IBD cases
adds to existing evidence as we extend
analyses with a comparison with thera-
peutic alternatives, which may help con-
trol for confounding bias. Notably, we
observed a potential signal for IBD and
CD, whereas Abrahami et al. (2) sug-
gested an increased risk of IBD and
UC. Preclinical studies on mouse models
suggest that DPP4ismay alleviate inflam-
matory disease and are protective
against colitis (5). Some clinical studies
indicate that the concentration of the
DPP4 enzyme in serum may be inversely
associated with IBD activity scores (5).
More studies are needed to further
explore the association and the under-
lying mechanism.
Our study has limitations. We were
unable to fully control for confounding as
the FAERS database is prone to reporting
bias and channeling bias and cannot be
used to calculate incidence. Additionally,
cases were often missing data on comor-
bidities, previous treatment, or the dura-
tion of treatment. Finally, although our
analysis suggests a weak-to-moderate
signal of IBD risk for DPP4i use, the
elevated RORs are not precise due to a
limited number of events. Future large
population-based studies are needed to
assess the risk of this rare event.
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